<DOC>
	<DOC>NCT01498055</DOC>
	<brief_summary>To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung cancer.</brief_summary>
	<brief_title>Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study</brief_title>
	<detailed_description>A randomized controlled trail on the efficacy and safety of autologous cytokine-induced killer (CIK) cells infusion treatment in advanced primary lung cancer</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>18~70 year old, KPS score &gt;50 points, estimate survival &gt; 3 months; Primary lung cancer patients after chemotherapy or radiation therapy; Primary lung cancer patients after targeted therapy; Primary lung cancer patients with lung function can not accept operation or unwilling to operation; Primary lung cancer recurrence or surgery can't complete resection; Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf, etc.); No serious mental illness and no serious heart, liver, kidney diseases, unincorporated other potentially lethal diseases; Patients Voluntary attempt, and informed consent. History of cardiovascular disease: congestive heart failure &gt; New York heart association (NYHA) level II, unstable angina patients (resting when the angina symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of myocardial infarction; Cachexia; or other deadly diseases; Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit; Active infection; Pregnant or lactating women At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents); Now or recently will join another experimental clinical study ; Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, HIV infections, etc.), or influence on the results of clinical trials for analysis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>CIK cells</keyword>
	<keyword>therapy</keyword>
</DOC>